{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"48","value":"157"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Mean terminal half-life (±SD)","dispersionType":"Standard Deviation","groups":[{"description":"Visilizumab, Tacrolimus and Methotrexate. All participants.","id":"OG000","title":"First Study Stage: Study Treatment"}],"paramType":"MEAN","populationDescription":"All participants","reportingStatus":"POSTED","timeFrame":"Up to 205 hours","title":"Pharmacodynamics of Visilizumab - Test 2","type":"SECONDARY","unitOfMeasure":"hours"}